AZD7325 Japan multiple ascending dose (MAD) Study - JMAD

Exclusion Criteria

• - Significant illness, as judged by the investigator, within 2 weeks of Day 1
• - Enrollment in another concurrent investigational study or intake of an
• investigational drug within 4 months prior to the screening visit
• - Blood loss in excess of 200 mL within 30 days of Day 1, in excess of 400 mL
• within 90 days of Day 1, or in excess of 1200 mL within 1 year of Day 1
• - Clinically relevant abnormalities in physical examinations, vital signs,
• clinical chemistry, hematology or urinalysis as judged by the investigator
• and/or sponsor